Thank you to all our donors!
Listed below are supporters who have given a cumulative contribution of over USD or EUR 10,000 since 2003, as well as collaborative funding partners.
Private donors
- Grant period: 2021
- Total amount: BRL 1 million
- Support to DNDi’s work on R&D and promotion of access to new treatments for neglected patients in Latin America
- Grant period: 2020
- Total amount: BRL 1 million
- Support to DNDi’s work on R&D and promotion of access to new treatments for neglected patients in Latin America
- Grant period: 2018
- Total amount: BRL 1.7 million
- Support to DNDi’s Chagas disease and leishmaniasis programmes in Latin America
- Grant period: 2017
- Total amount: BRL 1.5 million
- Support to DNDi’s Chagas disease and leishmaniasis programmes in Latin America
- Grant period: 2016
- Total amount: BRL 1.5 million
- Support to DNDi’s Chagas disease and leishmaniasis programmes in Latin America
- Grant period: 2013-2014
- Total amount: BRL 2 million
- Support to DNDi’s Latin America office
- Grant period: 2012
- Total amount: EUR 400,000
- Support to DNDi initiative
- Link to press release
- Grant period: 2020-2023
- Support to the project macrofilaricides for onchocerciasis
- Total amount: USD 14.254 million
- Link to press release
- Grant period: 2020-2023
- Support to the project acoziborole for human African trypanosomiasis (HAT)
- Total amount: USD 15 million
- Link to press release
- Grant period: 2015-2019
- Portfolio funding for human African trypanosomiasis (HAT), filarial diseases and visceral leishmaniasis
- Total amount: USD 60 million
- Supplemental grant for HAT (2017-2019): USD 4.8 million
- Link to press release
- Grant period: 2014-2016
- Support to DNDi activities through the “Innovative Fund Award”
- Total amount: USD 1 million
- Grant period: 2011-2015
- Support to screening for neglected tropical diseases
- Total amount: USD 4.3 million
- Grant period: 2011-2015
- Support to the adoption and implementation of new treatment options for visceral leishmaniasis in Asia
- Total amount: USD 7.6 million
- Link to press release
- Grant period: 2011-2014
- Support to the pre-clinical development of a macrofilaricidal drug candidate (flubendazole) for filarial diseases
- Total amount: USD 5.7 million
- Link to press release
- Grant period: 2009-2014
- Support to the clinical development of fexinidazole for human African trypanosomiasis
- Total amount: USD 19.4 million
- Link to press release
- Grant period: 2007-2012
- Support to lead optimization, preclinical, and start of clinical activities for human African trypanosomiasis/visceral leishmaniasis
- Total amount: USD 27.7 million
- Link to press release
- Grant period: 2013
- Total amount: USD 100,000
- Support to Chagas programme
- Link to press release
Dioraphte Foundation
- Grant period: 2021-2024
- Support to building the pathway for translational drug development of orally active new chemical entities for cutaneous leishmaniasis
- Total amount: EUR 850,000
- Grant period: 2020
- Total amount: EURO 100,000
- Support to human African trypanosomiasis – HAT programme
- Link to press release
- Grant period: 2021
- Support to joint project DNDi – Institut Pasteur Korea – Fundación Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucia (Fundación Medina) on discovery of new antiparasitic drug candidates and innovative modes of actions from microbial natural products for leishmaniasis and Chagas disease
- Total amount: EUR 995,251
- Link to press release
J.A. Delmas
- Grant period: 2022
- Support to the acquisition of an ambulance for the patients of the Dubreka clinical trial site (Guinea) on sleeping sickness
Leo Model Foundation, Inc.
- Grant period: 2018-2019
- Support to Global Antibiotic Research & Development Partnership (GARDP)
- Total amount: USD 100,000
- Grant period: 2017-2020
- Support to HCV
- Total amount: EUR 11,865,103
- Grant period: 2012-2018
- Total amount: USD 7,851,929
- Support to DNDi initiative
- Grant period: 2003-2012
- Total amount: USD 5,912,048
- Support to DNDi initiative
- Grant period: 2011-2012
- Support to the development and registration of the paediatric dosage form of benznidazole for Chagas disease
- Total amount: R$ 1 million
- Grant period: 2019-2023
- Support to DNDi initiative
- Total amount: EUR 20 million
- Grant period: 2014-2018
- Support to DNDi initiative and Global Antibiotic Research and Development Partnership (GARDP) from four Operating Centers: France, Japan, Australia, USA)
- Total amount: EUR 600,000
- Grant period: 2014-2018
- Support to DNDi initiative
- Total amount: EUR 20 million
- Grant period: 2009-2013
- Support to DNDi initiative
- Total amount: EUR 18.4 million
- Grant period: 2003-2008
- Support to DNDi initiative
- Total amount: EUR 25 million
- Link to press release
- Grant period: 2011
- Support to DNDi’s paediatric benznidazole formulation project
- Total amount: EUR 300’000
- Grant period: 2010-2011
- Support to the development and registration of the paediatric dosage form of benznidazole for Chagas disease
- Total amount: EUR 600,000
- Link to press release
- Grant period: 2009
- Support to DNDi malaria project (FACT) – study in Liberia with ASAQ
- Total amount: EUR 100,000
- Link to press release
- Grant period: 2011-2013
- Support to R&D for paediatric HIV programme
- Total amount: EUR 1,135,000
- Grant period: 2010
- Support to R&D opportunities for filarial diseases and paediatric HIV programmes
- Total amount: EUR 165,000
- Grant period: 2009-2012
- Support to DNDi initiative
- Total amount: EUR 400,000
- Grant period: 2020-2022
- Total amount: USD 1 million
- Support to clinical research and treatment for visceral leishmaniasis in East Africa & LEAP
- Grant period: 2017-2019
- Total amount: EUR 600,000
- Support to visceral leishmaniasis programmes in East Africa
- Grant period: 2014-2016
- Total amount: USD 700’000
- Support to research and treatment for visceral leishmaniasis
- Grant period: 2009-2013
- Total amount: USD 2.3 million
- Support to visceral leishmaniasis programmes in Africa
- Grant period: 2007
- Total amount: EUR 650,000
- Support to visceral leishmaniasis programmes in Africa
Other private foundations and individuals
- Bennett Shapiro and Fredericka Foster, USA
- Brian Mercer Charitable Trust, UK
- Charina Endowment Fund, USA
- Clifford N. Burnstein & Sabra C. Turnbull, USA
- craigslist Charitable Fund, USA
- David and Lisa U’Prichard, USA
- Family of Richard Rockefeller, USA
- Fondation André & Cyprien, Switzerland
- Fondation ARPE, Switzerland
- Fondation de bienfaisance du groupe Pictet, Switzerland
- Fondation Pro Victimis, Switzerland
- George H. Stout, USA
- Goldman, Sachs & Co., USA
- Guy’s, King’s and St Thomas’, Giving Week, UK
- Harlan and Sally Weisman, USA
- Jeff Nelson, USA
- Leopold Bachmann Foundation, Switzerland
- Dr Margaret Golden, USA
- Marsha Fanucci, USA
- Meena and Liaquat Ahamed, USA
- P B & K Family Foundation, USA
- Rockefeller Brothers Fund, USA
- Ronald L. Thatcher, USA
- Sandoz Family Foundation, Switzerland
- Sasakawa Peace Foundation, Japan
- Starr International Foundation, Switzerland
- Steve Rabin and Jonathan Winslow, USA
- The Broder Family Foundation, USA
- The Peter and Carmen Lucia Buck Foundation, USA
- The Robin O’Brien Fund, USA
- The Stainman Family Foundation, USA
- Zegar Family Fund, USA
- Other private foundations and individuals who would like to remain anonymous
- Grant period: 2019-2022
- Support to Ravidasvir regulatory activities (hepatitis C)
- Total amount: EUR 1,893,595
- Link to press release
- Grant period: 2021
- Support for the COVID-19 response: Coordinating the multi-country, African-led ANTICOV clinical trial; accelerating and facilitating research and scientific exchange in low- and middle-income countries; and advocating for equitable access globally to COVID-19 health technologies
- Grant period: 2018
- Support to the sustainable elimination of African sleeping sickness through the development and delivery of breakthrough treatments for neglected patients
- Term: 5 years
- Support to Global Access Program for the Most Neglected Patients
- Total amount: JPY 1 billion
- Link to announcement
- Grant period: 2020-2022
- Support the elimination of HAT in the DRC: increasing access to the first all-oral treatment
- Grant period: 2013
- Total amount: USD 100,000
- Support to DNDi initiative
- Link to press release
- Grant period: 2013-2016
- Total amount: CHF 750,000
- Support to Paediatric HIV – “Developing drug granules for children with HIV and TB”
- Grant period: 2006-2009
- Total amount: CHF 1,080,000
- Drug development for Chagas disease and Human African Trypanosomiasis
- Grant period: 2005
- Total amount: CHF 170,000
- Drug development for Chagas disease and Human African Trypanoyomiasis
- Grant period: 2022-2023
- Support to leishmaniasis part 2 (NCE2): 21st Century treatments for the sustainable elimination of leishmaniasis
- Total amount: EUR 5,684,371
- Link to press release
- Grant period: 2021-2022
- Support to the development of Target Product Profiles for snake antivenom products
- Total amount: USD 276,768
- Grant period: 2021-2022 (extended to 2023)
- Support to the design and implementation of a translational drug development platform for COVID-19 to generate preclinical evidence in support of treatment arms of the ANTICOV clinical trial
- Total amount GBP 2,444,357 (including 980,066 extension)
- Grant period: 2019-2022
- 21stCentury treatments for the sustainable elimination of leishmaniasis
- Total amount: EUR 11,357,755
- Link to press release
- Grant period: 2012-2017
- Support to a study to validate PCR and other biomarkers for Chagas disease
- Total amount: USD 3,000,000 + USD 85,182 as supplemental funding + USD 494,631 as additional funding
- Link to press release
- Grant period: 2011-2014
- Support to the Phase II clinical trial of E1224 for Chagas disease
- Total amount: EUR 1,999,801
- Link to press release
- Grant period: 2021-2023
- Moonshot – Development of an investigational new drug from a novel, open-science, orally available small molecule antiviral targeting SARS-CoV-2 main protease
- Total amount: GBP 8 million
- Link to press release
Transparency
We publish timely and transparent information on our funding and projects.
Fundraising policy
To develop our activities and achieve our objectives, we seek diversified sources of funding
